New data show a decrease in COVID-19 deaths in the United States; long-term exposure to low levels of air pollution increases mortality risk; Moderna pressured to ramp up vaccine production.
Following declines in COVID-19 cases reported in the United States over the past several weeks, national data now show deaths have followed suit and are on the decline, Axios reports. The country is reporting around 102,000 cases per day, marking a 22% decline over the past 2 weeks, and the virus is taking the lives of around 1800 Americans per day—a decrease by a nationwide average of about 13%. Despite the drop in numbers, unvaccinated individuals in heavily unvaccinated areas remain at risk and the virus’ death toll continues to be about equivalent to the that of 9/11 every 2 days.
A new study published in The Lancet Planetary Health revealed that long-term exposure to permissible levels of air pollution increases the risk of mortality, particularly among individuals living in areas of low socioeconomic status. Researchers sought to determine whether existing US Environmental Protection Agency standards were sufficient in protecting health with regard to 3 air pollutants: particulate matter less than 2.5 mcg/m3 in diameter (PM2.5), nitrogen dioxide (NO2), and summer ozone (O3). Data were gleaned from Medicare enrollees participating in the program from 2000 to 2016. Findings translated to tens of thousands of additional deaths per year per unit difference in exposure, authors said.
Moderna is resisting pressure from the Biden administration to ramp up global donations of its COVID-19 vaccine in 2022, according to Politico. The company has agreed to supply 500 million doses to low- and middle-income countries as part of the COVAX program and agreed to donate 34 million doses this year. Moderna also recently announced it would open a vaccine production site in Africa to produce up to 500 million doses of the COVID-19 shot each year. However, STAT News reports the COVAX program is failing on its promise to deliver vaccines to these nations, and many are left in the dark about when deliveries will arrive.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More